The global 3D printed drugs market is anticipated to grow at a CAGR of 9.1% during the forecast period (2021-2027). The key companies across the globe are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2020, Aprecia Pharmaceuticals LLC, a 3D printed pharmaceuticals company, has announced a partnership with Purdue University. This partnership was done for the development of various projects by using Aprecia ZIpDose technology in the 3D printing of drugs.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/3d-printed-drugs-market
Apart from this, in April 2020, FabRx Ltd., a biotech spin-out from University College London (UCL) in the UK, has announced the launch of the M3DIMAKER system, a pharmaceutical 3D printer developed for the production of customized medicine. M3DIMAKER 3D printer is controlled by a specialized platform that allowing users to pick the dosage recommended by the pharmacist and clinician. The app also includes a data matrix reader and fingerprint access control, ensuring reliability and stability. In September 2019, the system was first launched in Switzerland at the ILMAC Exhibition and after testing, now it is available for the market.
A Full Report of Global 3D Printed Drugs Market is Available at: https://www.omrglobal.com/industry-reports/3d-printed-drugs-market
In March 2021, CELLINK Inc, a Swedish-based 3D bioprinter manufacturer, has acquired MatTek Corp., an in-vitro technology specialist, for around $68 million. Also, in April 2021, Materialise NV, a Belgian-based 3D printing service provider, has acquired Link3D, a software development company by the end of the year 2021. This acquisition will help to remove the complexities associated with scaling 3D printing as part of a connected, industrial manufacturing process. Besides, in February 2021, Merck KGaA, a science and technology company, and AMCM, a Germany-based company, has announced the agreement on the 3D printing of tablets. Thus, the mergers & acquisitions, partnership by the major players, and new and innovative product development in the 3D printed drugs market are driving the growth during the forecast period.
Global 3D Printed Drugs Market Report Segment
By Dosage Forms
- Tablet
- Capsules
- Multi-Drug Implant
- Nanoparticles
- Solutions
- Nano suspension
- Encapsulated within a polymer
- Implant
By Technology
- Inkjet Printing
- Zip Dose
- Thermal Inkjet (TIJ) Printing
- Fused Deposition Modelling (FDM)
- Stereolithography (SLA)
- Others
By Application
- Dental
- Hearing & Audibility Aid
- Medical Implants
- Neurology
- Orthopedic
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
